Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Trial of Concurrent RAD001 (Everolimus) With Temozolomide/Radiation Followed by Adjuvant RAD001/Temozolomide in Newly Diagnosed Glioblastoma

NCT01062399 is registered in ClinicalTrials.gov with Radiation Therapy Oncology Group as lead sponsor.

NCT NCT01062399
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01062399 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Trial of Concurrent RAD001 (Everolimus) With Temozolomide/Radiation Followed by Adjuvant RAD001/Temozolomide in Newly Diagnosed Glioblastoma
Lead sponsor
Radiation Therapy Oncology Group
Phase
Phase 1/2
Overall status
Completed
Start date
December 31, 2010
Completion date
May 20, 2022
Enrollment
279 (actual)
Sites
36

Conditions

As the registry lists them; a condition with its own page is linked.

brain and central nervous system tumors